Table 2

Changes in total LBM in kilograms

Longitudinal studies
Author (year)
Participants (N)Baseline
mean±SD
(95% CI)
12 Months
mean±SD
(95% CI)
12–31 months
mean±SD
% ChangePT (nmol/L)
Base-post GAHT
TW
Mueller et al (2011)118459.6
(54.6–64.6)
57.2
(54.0–64.1)
−4.0<0.00513.6–0.6
Wierckx et al (2014)4540 (oral oestrogen)
12 (transdermal oestrogen)
56.0±7.5
62.6±9.3
53±8
59.7±8.1
−5.4
−4.6
<0.001
<0.05
18.0–0.4
19.7–0.5
Gava et al (2016)3820 (cyproterone acetate)
20 (leuprolide acetate)
51.7±8.3
50.2±7.0
49.9±7.8
49.8±6.7
−3.5
−0.8
>0.05
>0.05
16.3–0.7
22.2–0.7
Auer et al (2018)404559.5±8.7
(56.9–62.0)
57.5±12
(53.9–60.2)
−3.4<0.00117.5–1.9
Klaver et al (2018)1517957.2±8.355.5
(54.9–56.1)
−3.0<0.001
Tack et al (2018)362147.0±6.444.8±6.3−4.7<0.0115.2–8.8
Haraldsen et al (2007)511254.4±6.252.2−4.0<0.00116.8–8.6
Van Caenegem et al (2015)414957.4±8.755.1±8.7−4.0<0.00119.0–0.5
Cross-sectional studies
Author (year)
Participants (N)TW baseline
mean±SD
TW 48 months
mean±SD
CM
mean±SD
% DifferencePT
(nmol/L)
TW
TWCM
Lapauw et al (2008)54234651.2±8.461.8±7.9−17.2<0.0011.1
Haraldsen et al (2007)51127754.4±6.259.1±5.7−8.0<0.0516.8
Van Caenegem et al (2015)41494957.4±8.761.3±6.8−6.4<0.0519.0
  • Data are from dual energy X-ray absorptiometry scans.

  • CM, cismen; LBM, lean body mass; TW, transwomen.